Which interventions appear most often on Chronic Myelogenous Leukemia, BCR-ABL1 Positive trial records?

Laboratory Biomarker Analysis is the most-linked intervention name on Chronic Myelogenous Leukemia, BCR-ABL1 Positive records (3 trial links), followed by imatinib mesylate. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Chronic Myelogenous Leukemia, BCR-ABL1 Positive?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Chronic Myelogenous Leukemia, BCR-ABL1 Positive: early-phase trial registry

Q: How many clinical trials are there for Chronic Myelogenous Leukemia, BCR-ABL1 Positive?

PlainTrial tracks 11 US clinical trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive, of which 1 are currently recruiting.

Compiled by PlainTrial · August 8, 2026

1 of 11 indexed Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Chronic Myelogenous Leukemia, BCR-ABL1 Positive: 11 US clinical trials tracked, 1 recruiting.

Chronic Myelogenous Leukemia, BCR-ABL1 Positive is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.

Enrollment posture brief

Registry condition chronic-myelogenous-leukemia-bcr-abl1-positive

Volume-matched condition peers

Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)

Open-enrollment share among volume-matched conditions near Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Chronic Myelogenous Leukemia, BCR-ABL1 Positive lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Myelogenous Leukemia, BCR-ABL1 Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Chronic Myelogenous Leukemia, BCR-ABL1 Positive is recruiting below its size-band peers.

1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
One sponsor concentrates Chronic Myelogenous Leukemia, BCR-ABL1 Positive research.

National Cancer Institute (NCI) accounts for 5 of 11 trials (45.5%). 6 distinct sponsors appear on at least one study for this condition label.
Most Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials plan to enrol fewer than 100 people.

Median target enrolment is 46 among the 11 trials that report a genuine target (sentinel values excluded). 11 of those (100%) plan for fewer than 100 participants.
Chronic Myelogenous Leukemia, BCR-ABL1 Positive research is mostly interventional.

11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1 58 participants

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

M.D. Anderson Cancer Center

NCT03630991

ACTIVE NOT RECRUITING Phase 2 31 participants

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

NCT03399773

ACTIVE NOT RECRUITING NA 30 participants

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Ohio State University Comprehensive Cancer Center

NCT05972577

ACTIVE NOT RECRUITING Phase 1 16 participants

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

NCT03622788

COMPLETED Phase 2 80 participants